Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the target of a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 239,200 shares, a decline of 6.9% from the May 15th total of 256,900 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average daily volume of 92,400 shares, the short-interest ratio is presently 2.6 days.

Aileron Therapeutics Stock Down 0.9 %

NASDAQ ALRN opened at $3.22 on Monday. Aileron Therapeutics has a twelve month low of $1.01 and a twelve month high of $7.42. The stock has a market cap of $69.52 million, a P/E ratio of -1.01 and a beta of 2.11. The company’s 50-day simple moving average is $4.12 and its 200 day simple moving average is $4.29.

Aileron Therapeutics (NASDAQ:ALRN) last issued its earnings results on Monday, May 20th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.72). Research analysts anticipate that Aileron Therapeutics will post -0.93 earnings per share for the current year.

Insider Activity at Aileron Therapeutics

In other Aileron Therapeutics news, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $4.21, for a total value of $85,526.15. Following the completion of the sale, the insider now owns 1,779,306 shares of the company’s stock, valued at $7,490,878.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, major shareholder Of Texas/Texas Am I. University sold 9,577 shares of Aileron Therapeutics stock in a transaction on Monday, June 10th. The shares were sold at an average price of $3.30, for a total value of $31,604.10. Following the transaction, the insider now owns 1,768,250 shares in the company, valued at approximately $5,835,225. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $4.21, for a total value of $85,526.15. Following the sale, the insider now owns 1,779,306 shares of the company’s stock, valued at approximately $7,490,878.26. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,011 shares of company stock valued at $227,117. Insiders own 5.57% of the company’s stock.

Institutional Investors Weigh In On Aileron Therapeutics

A hedge fund recently bought a new stake in Aileron Therapeutics stock. Texas Capital Bank Wealth Management Services Inc purchased a new stake in Aileron Therapeutics, Inc. (NASDAQ:ALRN) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,773 shares of the company’s stock, valued at approximately $48,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.32% of Aileron Therapeutics as of its most recent SEC filing. Institutional investors own 90.89% of the company’s stock.

Analysts Set New Price Targets

ALRN has been the subject of several recent research reports. LADENBURG THALM/SH SH upped their price target on Aileron Therapeutics from $9.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Brookline Capital Management upgraded Aileron Therapeutics to a “strong-buy” rating in a research report on Thursday, May 30th.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).